The EIF2AK3 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 cell line, featuring targeted disruption of the EIF2AK3 gene. EIF2AK3 encodes the protein kinase PERK, a critical sensor of endoplasmic reticulum (ER) stress. This knockout model provides a loss-of-function genetic background to dissect PERK-dependent signaling without relying on pharmacological inhibition, enabling robust investigation of the unfolded protein response (UPR) and integrated stress response (ISR) in cancer biology.
The parental A-549 cell line was established from the lung adenocarcinoma of a 58-year-old male and harbors a KRAS G12S mutation. These cells are widely used as a model of type II alveolar epithelial cells and are a standard system for studying lung adenocarcinoma pathobiology, including oncogenic signaling, drug resistance, and tumor microenvironment interactions.
PERK, normally bound to BiP/GRP78 in the ER membrane, dimerizes and autophosphorylates upon accumulation of misfolded proteins. Active PERK phosphorylates eIF2??, attenuating global translation while selectively increasing ATF4 translation. ATF4 transcriptionally upregulates genes for amino acid metabolism, redox control, and autophagy. Under prolonged ER stress, PERK signaling induces CHOP (DDIT3) and GADD34 (PPP1R15A), promoting apoptosis. Upstream activators include thapsigargin, tunicamycin, hypoxia, nutrient deprivation, and oxidative stress. PERK also cross-talks with IRE1??, ATF6, and the NRF2/Keap1 antioxidant axis.
In the context of A-549 lung adenocarcinoma cells carrying a KRAS G12S mutation, the PERK knockout enables dissection of how ER stress signaling intersects with oncogenic drivers to modulate tumor cell proliferation, survival, and therapeutic sensitivity. The polyclonal knockout population avoids clonal selection artifacts and better represents the heterogeneous response typical of tumor cell pools. This model is particularly valuable for studying the role of PERK in adaptation to microenvironmental stresses, such as hypoxia and nutrient deprivation, and for evaluating how loss of PERK alters sensitivity to chemotherapy or targeted agents.
The EIF2AK3 Knockout A-549 Polyclonal Cells enable Western blot analysis of PERK, phospho-eIF2??, ATF4, and CHOP; RT-qPCR of ATF4, CHOP, and GADD34; and functional studies with ER stress inducers thapsigargin or tunicamycin. Additional assays include cell viability, apoptosis, phospho-signaling analysis, immunofluorescence, RNA-seq, and drug sensitivity testing with the PERK inhibitor GSK2656157. These polyclonal knockout cells provide a robust platform for investigating UPR mechanisms in lung adenocarcinoma, screening PERK inhibitors, and evaluating resistance pathways. For further details or custom knockout requests, please contact Ascent Research.
